ISRCTN24219839 https://doi.org/10.1186/ISRCTN24219839

# Trial of PACEBOM versus CHOP in histologically aggressive non-Hodgkins lymphoma

| | | |
|---|---|---|
| **Submission date**<br>01/07/2001 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[X] Results<br>[_] Individual participant data |
| **Registration date**<br>01/07/2001 | **Overall study status**<br>Completed | |
| **Last Edited**<br>01/02/2012 | **Condition category**<br>Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**Protocol serial number**
LY3

## Study information

**Scientific Title**

**Study objectives**
Not provided at time of registration

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkins)

### Interventions
Patients were randomised to one of two regimens:
1. CHOP Regimen: Multi-drug chemotherapy with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP) repeated every 28 days. A minimum of six courses to be given with two courses beyond the attainment of complete response
2. PACEBOM Regimen: Multi-drug chemotherapy with prednisolone, adriamycin, cyclophosphamide and etoposide (PACE) alternating every 7 days with bleomycin, vincristine and methotrexate (BOM). Six cycles of PACE and five of BOM to be given

### Intervention Type
Other

### Phase
Not Specified

### Primary outcome(s)
Not provided at time of registration

### Key secondary outcome(s))
Not provided at time of registration

### Completion date
31/10/1992

## Eligibility

### Key inclusion criteria
1. Aged 16 to 69 years
2. Previously untreated histologically aggressive lymphoma with a large cell component: Diffuse large cell, Diffuse immunoblastic, Diffuse mixed cell
3. Stages II-IV
4. No contraindications to treatment protocols

**Participant type(s)**
Patient

**Healthy volunteers allowed**
No

**Age group**
Not Specified

**Sex**

**Key exclusion criteria**
Patients with Burkitt's and lymphoblastic lymphoma to be excluded

**Date of first enrolment**
01/11/1987

**Date of final enrolment**
31/10/1992

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**UKCCCR Register Co-ordinator**
London
United Kingdom
NW1 2DA

# Sponsor information

**Organisation**
Cancer Research UK (CRUK) (UK)

**ROR**
https://ror.org/054225q67

# Funder(s)

**Funder type**
Charity

**Funder Name**
Cancer Research UK

**Alternative Name(s)**
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**
Other non-profit organizations

**Location**
United Kingdom

**Funder Name**
Lymphoma Research Trust

**Funder Name**
Lisa Lear Fund

**Funder Name**
Isle of Man Anti-Cancer Association

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

## Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/07/1996 | | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |